NTEC News and Press, Intec Pharma Ltd. From 04/01/19

JERUSALEM , April 1, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Company management will participate in the upcoming HC Wainwright Global Life Sciences Conference. HC Wainwright Global Life Sciences Conference Dat...

The following slide deck was published by Intec Pharma Ltd. in conjunction with this Read more ...

JERUSALEM , March 13, 2019 /PRNewswire/ --   Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company's presentation time at Barclays Global Healthcare Conference has been changed as follows. Barclays Global Healthcare Conference Date: ...

JERUSALEM , Feb. 28, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Company management will participate at the following upcoming investment conferences in March.  Cowen 39th Annual Health Care Conference Date: March 11-...

Intec Pharma (NASDAQ: NTEC ): FY GAAP EPS of -$1.40. More news on: Intec Pharma, Earnings news and commentary, Healthcare stocks news, Read more ...

JERUSALEM , Feb. 27, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the fourth quarter and year ended December 31, 2018 and provides a corporate update.  Highlights of the fourth quarter 2018 and recent wee...

Thinly traded micro cap Intec Pharma (NASDAQ: NTEC ) is up  1%  premarket on light volume in response to positive preliminary results from a pharmacokinetic (PK) study comparing its Accordion Pill Carbidopa/Levodopa (AP-CD/LD) 50/500mg dosed three times daily to 1.5 tablets of CD...

JERUSALEM , Feb. 19, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces the preliminary results from a pharmacokinetic (PK) study comparing the Company's Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD) 50/500mg dosed three times dai...

Dosing is underway in a Phase 1 clinical trial evaluating Intec Pharma's (NASDAQ: NTEC ) Accordion Pill containing tetrahydrocannabinol (THC), AP-THC. The study will assess the safety, tolerability and pharmacokinetics in 18 healthy volunteers. More news on: Intec Pharma, Healthcare sto...

JERUSALEM , Jan. 2, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces the dosing of the first patient in a Phase 1 pharmacokinetic (PK) study of AP-THC, its proprietary Accordion Pill™ platform containing synthetic tetrahydrocanna...